Management of BRCA mutation carriers with pancreatic adenocarcinoma

Keyphrases

• Pancreatic Ductal Adenocarcinoma 100%
• BRCA mutation Carriers 100%
• Pancreatic Adenocarcinoma 100%
• PARP Inhibitor (PARPi) 20%
• Precision Medicine 10%
• DNA Repair 10%
• Clinically Significant 10%
• Family History 10%
• Germ Cells 10%
• Risk Assessment 10%
• Genetic Modification 10%
• Conventional Therapy 10%
• Genetic Heterogeneity 10%
• Personal History 10%
• Advanced Disease 10%
• BRCA Carriers 10%
• 5-year Survival 10%
• DNA Double-strand Break Repair 10%
• Recent Update 10%
• Treatment Implications 10%
• Median Overall Survival 10%
• Platinum Sensitivity 10%
• Germline BRCA mutation 10%
• Inherited Syndromes 10%
• Dismal Prognosis 10%
• Platinum Therapy 10%
• Maintenance Strategy 10%
• Germline BRCA 10%
• NCCN Guidelines 10%
• DNA Damage Repair Deficiency 10%
• Hereditary mutations 10%
• Biologic Subtype 10%
• ASCO Guidelines 10%

Biochemistry, Genetics and Molecular Biology

• Germline 100%
• Germ Cell 100%
• DNA Repair 66%
• Poly ADP Ribose Polymerase 66%
• Gene Mutation 33%
• Genetic Heterogeneity 33%
• Survival Rate 33%
• Overall Survival 33%
• Genomics 33%
• Double-Strand DNA Break 33%

Medicine and Dentistry

• BRCA Mutation 100%
• Pancreas Adenocarcinoma 100%
• Germ Cell 27%
• DNA Repair 18%
• Biological Product 18%
• PARP Inhibitor 18%
• Survival Rate 9%
• Personalized Medicine 9%
• Gene Mutation 9%
• Family History 9%
• Overall Survival 9%
• Genetic Heterogeneity 9%
• Diseases 9%
• Double-Strand DNA Break 9%